Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,923Revenue $M751Net Margin (%)-20.4Altman Z-Score10.7
Enterprise Value $M21,602EPS $-0.9Operating Margin %-16.5Piotroski F-Score2
P/E(ttm)--Beneish M-Score-1.7Pre-tax Margin (%)-20.6Higher ROA y-yY
Price/Book9.010-y EBITDA Growth Rate %--Quick Ratio4.3Cash flow > EarningsN
Price/Sales25.55-y EBITDA Growth Rate %--Current Ratio5.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-6.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-9.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M160ROIC % (ttm)-8.0Gross Margin Increase y-yN

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNJoel Greenblatt 2015-03-31 Buy $90.28 - $129.14
($105.95)
$ 136.7829%New holding4,195
BMRNJoel Greenblatt 2014-12-31 Sold Out $67.27 - $94.19
($83.42)
$ 136.7864%Sold Out0
BMRNJoel Greenblatt 2014-09-30 Buy $55.78 - $73
($65.82)
$ 136.78108%New holding3,885
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 136.78119%Sold Out0
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 136.78142%Reduce 69.03%40,700
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 136.78200%Reduce 60.99%131,400
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 136.78280%Sold Out0
BMRNGeorge Soros 2012-03-31 Add0.11%$33.68 - $38.34
($32.99)
$ 136.78315%Add 300.00%300,000
BMRNGeorge Soros 2011-12-31 Reduce-0.05%$30.07 - $35.38
($32.81)
$ 136.78317%Reduce 57.14%75,000
BMRNGeorge Soros 2011-06-30 Add0.07%$24.93 - $28.455
($26.32)
$ 136.78420%Add 862.36%191,510
BMRNMeridian Funds 2011-03-31 Reduce-0.28%$23.46 - $28.29
($25.46)
$ 136.78437%Reduce 51.54%348,800
BMRNGeorge Soros 2011-03-31 Buy 0.01%$23.46 - $28.29
($25.46)
$ 136.78437%New holding19,900
BMRNGeorge Soros 2010-09-30 Sold Out -0.02%$18.24 - $23.09
($20.93)
$ 136.78554%Sold Out0
BMRNMeridian Funds 2010-03-31 Add0.13%$18.75 - $23.81
($20.92)
$ 136.78554%Add 20.83%795,900
BMRNGeorge Soros 2010-03-31 Add$18.75 - $23.81
($20.92)
$ 136.78554%Add 35.87%30,300
BMRNGeorge Soros 2009-12-31 Buy 0.01%$15.49 - $18.98
($17.17)
$ 136.78697%New holding22,300
BMRNMeridian Funds 2009-09-30 Buy 0.53%$13.86 - $18.33
($15.84)
$ 136.78764%New holding658,700
BMRNBill Gates 2009-06-30 Sold Out -0.02%$11.92 - $15.94
($13.79)
$ 136.78892%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SPIEGELMAN DANIEL KEVP, CFO 2015-06-05Sell1,649$122.311.8view
FUCHS HENRY JEVP, Chief Medical Officer 2015-06-05Sell1,864$122.3211.78view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-06-04Sell1,362$122.3511.75view
SPIEGELMAN DANIEL KEVP, CFO 2015-06-01Sell5,523$124.739.62view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-06-01Sell377$123.7610.48view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-05-26Sell1,625$126.558.04view
BIENAIME JEAN JACQUESCEO 2015-05-21Sell1,500$126.18.43view
SPIEGELMAN DANIEL KEVP, CFO 2015-05-18Sell34,078$1305.18view
SPIEGELMAN DANIEL KEVP, CFO 2015-05-18Sell2,059$124.779.59view
FUCHS HENRY JEVP, Chief Medical Officer 2015-05-18Sell1,864$124.789.58view

Quarterly/Annual Reports about BMRN:

News about BMRN:

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 

More From Other Websites
Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress -... Jul 01 2015
Should The Biotech Bubble Be Feared? Jun 30 2015
Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog Jun 30 2015
BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog Jun 30 2015
​Sarepta CEO: Teamwork has been key to quick progress on Duchenne drug Jun 29 2015
BioMarin, Sarepta Muscular Dystrophy Drugs Progress Jun 29 2015
BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable... Jun 29 2015
8:31 am Biomarin Pharm announces FDA acceptance for review, its submission of a New Drug Application... Jun 29 2015
BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable... Jun 29 2015
Sarepta Submits DMD Drug for FDA Approval Review Jun 29 2015
BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog Jun 26 2015
BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy... Jun 25 2015
BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy... Jun 25 2015
The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases Jun 25 2015
Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog Jun 24 2015
BioMarin CEO: Excited about dwarfism drug potential Jun 23 2015
5 Biotech Stocks to Trade for Gains Jun 23 2015
BioMarin Pharmaceutical (BMRN) Stock Is the 'Chart of the Day' Jun 22 2015
BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog Jun 19 2015
BioMarin: Too Expensive? Jun 19 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK